Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0034 in Acute Generalized Pustular Psoriasis Flare
NCT06231381Phase 2Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing HB0034 with Placebo (2 arms). Primary endpoint: Proportion of subjects who achieved GPPGA pustulation subscore of 0/1 (no/almost no visible pustules) at 1 week. Started Feb 2024; status: recruiting.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06231381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231381.